BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lane DA, Lip GY. Use of the CHA 2 DS 2 -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Circulation 2012;126:860-5. [DOI: 10.1161/circulationaha.111.060061] [Cited by in Crossref: 222] [Cited by in F6Publishing: 77] [Article Influence: 22.2] [Reference Citation Analysis]
Number Citing Articles
1 Gokcal E, Horn MJ, Gurol ME. The role of biomarkers and neuroimaging in ischemic/hemorrhagic risk assessment for cardiovascular/cerebrovascular disease prevention. Handb Clin Neurol 2021;177:345-57. [PMID: 33632452 DOI: 10.1016/B978-0-12-819814-8.00021-4] [Reference Citation Analysis]
2 Schwab K, Smith R, Wager E, Kaur S, Alvarez L, Wagner J, Leung H. Identification and early anticoagulation in patients with atrial fibrillation in the emergency department. Am J Emerg Med 2021;44:315-22. [PMID: 32331958 DOI: 10.1016/j.ajem.2020.04.019] [Reference Citation Analysis]
3 Wang CL, Wu VC, Tu HT, Huang YT, Chen SW, Chu PH, Wen MS, Huang HL, Chang SH. Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation. J Thromb Thrombolysis 2021. [PMID: 34557973 DOI: 10.1007/s11239-021-02570-9] [Reference Citation Analysis]
4 Sweis R, Biller J. Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation. Curr Treat Options Cardiovasc Med 2016;18:24. [PMID: 26909818 DOI: 10.1007/s11936-016-0446-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Holmes DR, Reddy VY. Left Atrial Appendage and Closure: Who, When, and How. Circ: Cardiovascular Interventions 2016;9. [DOI: 10.1161/circinterventions.115.002942] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
6 Jang SM, Bahjri K, Tran H. Safety and Efficacy of Direct Oral Anticoagulants for Atrial Fibrillation in Patients with Renal Impairment. Pharmacy (Basel) 2020;8:E30. [PMID: 32143504 DOI: 10.3390/pharmacy8010030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol 2020;19:9. [PMID: 31954408 DOI: 10.1186/s12933-019-0983-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
8 Lim HY, Ho P. Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population. Dent J (Basel) 2016;4:E7. [PMID: 29563449 DOI: 10.3390/dj4010007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Li Y, Ding W, Wang H, Song N, Lin L, Wang Z, Zhong M, Zhang Y, Zhang W. Relationship of CHA2DS2-VASc and CHADS2 score to left atrial remodeling detected by velocity vector imaging in patients with atrial fibrillation. PLoS One 2013;8:e77653. [PMID: 24147047 DOI: 10.1371/journal.pone.0077653] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
10 Bloemen S, Zwaveling S, Ten Cate H, Ten Cate-Hoek A, de Laat B. Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing. PLoS One 2017;12:e0176967. [PMID: 28472104 DOI: 10.1371/journal.pone.0176967] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Alwafi H, Wong ICK, Banerjee A, Mongkhon P, Whittlesea C, Naser AY, Lau WCY, Wei L. Epidemiology and treatment of atrial fibrillation in patients with type 2 diabetes in the UK, 2001-2016. Sci Rep 2020;10:12468. [PMID: 32719438 DOI: 10.1038/s41598-020-69492-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Malaeb D, Hallit S, Dia N, Cherri S, Maatouk I, Nawas G, Salameh P, Hosseini H. Effects of sociodemographic and socioeconomic factors on stroke development in Lebanese patients with atrial fibrillation: a cross-sectional study. F1000Res 2021;10:793. [PMID: 34504688 DOI: 10.12688/f1000research.54236.2] [Reference Citation Analysis]
13 Qin D, Leef G, Alam MB, Rattan R, Munir MB, Patel D, Khattak F, Vaghasia N, Adelstein E, Jain SK, Saba S. Patient outcomes according to adherence to treatment guidelines for rhythm control of atrial fibrillation. J Am Heart Assoc 2015;4:e001793. [PMID: 25845930 DOI: 10.1161/JAHA.115.001793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
14 De Vecchis R, Cantatrione C, Mazzei D. Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent. J Clin Med Res 2016;8:153-61. [PMID: 26767085 DOI: 10.14740/jocmr2443w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
15 Aggarwal N, Selvendran S, Raphael CE, Vassiliou V. Atrial Fibrillation in the Young: A Neurologist's Nightmare. Neurol Res Int 2015;2015:374352. [PMID: 25922764 DOI: 10.1155/2015/374352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
16 Deshpande CG, Kogut S, Willey C. Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy. J Manag Care Spec Pharm 2018;24:430-9. [PMID: 29694285 DOI: 10.18553/jmcp.2018.24.5.430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Keser A, Özbek K, Katlandur H, Ulucan Ş. Peripheral Artery Disease and Atrial Fibrillation: The Dangerous Combination. J Am Coll Cardiol 2016;68:237-8. [PMID: 27386782 DOI: 10.1016/j.jacc.2016.03.594] [Reference Citation Analysis]
18 Malaeb D, Hallit S, Dia N, Cherri S, Maatouk I, Nawas G, Salameh P, Hosseini H. Effects of sociodemographic and socioeconomic factors on stroke development in Lebanese patients with atrial fibrillation: a cross-sectional study. F1000Res 2021;10:793. [PMID: 34504688 DOI: 10.12688/f1000research.54236.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Camm AJ, Lip GY, Caterina RD, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, Mcdonagh T, Moulin C, Popescu BA, Reiner Ž, Sechtem U, Anton Sirnes P, Tendera M, Torbicki A, Vahanian A, Windecker S, Vardas P, Al-attar N, Alfieri O, Angelini A, Blömstrom-lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M, Dalby Kristensen S, Kolh P, Le Heuzey J, Mavrakis H, Mont L, Perrone Filardi P, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW. Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012. Revista Española de Cardiología 2013;66:54.e1-54.e24. [DOI: 10.1016/j.recesp.2012.11.001] [Cited by in Crossref: 10] [Article Influence: 1.1] [Reference Citation Analysis]
20 Urooj F, Kulkarni A, Stapleton D, Kaluski E. New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. Clin Cardiol 2016;39:739-46. [PMID: 27716952 DOI: 10.1002/clc.22582] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
21 Alalwan MA, Al-Ohaid F, Alhajjaj HM, Al Hazeem A, AlJulaih GH, Al-Khedher R, Alshehri A, Jatoi NA. Stroke Prevention Therapy and Prevalence of Risk Factors Among Patients With Atrial Fibrillation at King Fahad University Hospital in Al Khobar: A Retrospective, Single-Center Study. Cureus 2021;13:e12493. [PMID: 33425559 DOI: 10.7759/cureus.12493] [Reference Citation Analysis]
22 Iqbal A, Rodriguez F, Schirmer H. Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. Curr Cardiol Rep 2015;17:64. [PMID: 26104508 DOI: 10.1007/s11886-015-0615-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Omae T, Inada E. New-onset atrial fibrillation: an update. J Anesth 2018;32:414-24. [PMID: 29523996 DOI: 10.1007/s00540-018-2478-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
24 Park SM, Jeong H, Jung MH, Hong KS, Hong MK, Bang CS, Kim CY. Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. Contemp Clin Trials 2017;60:51-5. [PMID: 28642210 DOI: 10.1016/j.cct.2017.06.011] [Reference Citation Analysis]
25 Mittal M, Aggarwal K, Littrell RL, Agrawal H, Alpert MA. Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?: Pharmacotherapy, cardiovascular outcomes, and hemodialysis. Hemodial Int 2015;19:S40-50. [DOI: 10.1111/hdi.12352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Heidenreich PA, Estes NAM 3rd, Fonarow GC, Jurgens CY, Kittleson MM, Marine JE, McManus DD, McNamara RL. 2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circ Cardiovasc Qual Outcomes 2021;14:e000100. [PMID: 33284642 DOI: 10.1161/HCQ.0000000000000100] [Reference Citation Analysis]
27 Wu J, Zhang Y, Liao X, Lei Y. Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review. Front Med (Lausanne) 2020;7:350. [PMID: 32903326 DOI: 10.3389/fmed.2020.00350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Shao IY, Claxton JS, Lutsey PL, Chen LY, MacLehose RF, Alonso A. Association of Type of Antidepressant Initiation with Bleeding Risk in Atrial Fibrillation Patients Taking Oral Anticoagulants. Drugs Real World Outcomes 2021;8:383-91. [PMID: 34014500 DOI: 10.1007/s40801-021-00258-3] [Reference Citation Analysis]
29 Sheibani R, Nabovati E, Sheibani M, Abu-Hanna A, Heidari-Bakavoli A, Eslami S. Effects of Computerized Decision Support Systems on Management of Atrial Fibrillation: A Scoping Review. J Atr Fibrillation 2017;10:1579. [PMID: 29250222 DOI: 10.4022/jafib.1579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Balaghi-inalou M, Parsa SA, Gachkar L, Andalib S. Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians’ Decision and CHA2DS2-VASc and HAS-BLED Scores. High Blood Press Cardiovasc Prev 2018;25:61-4. [DOI: 10.1007/s40292-017-0237-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
31 Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130:1847-1858. [PMID: 25294786 DOI: 10.1161/circulationaha.114.011204] [Cited by in Crossref: 165] [Cited by in F6Publishing: 66] [Article Influence: 20.6] [Reference Citation Analysis]
32 Adeleke I, Kersh JS, Sweitzer B. Perioperative management and optimization of atrial fibrillation for noncardiac surgery. Int Anesthesiol Clin 2022;60:16-23. [PMID: 34897218 DOI: 10.1097/AIA.0000000000000352] [Reference Citation Analysis]
33 Powers A, Loesch EB, Weiland A, Fioravanti N, Lucius D. Preemptive warfarin dose reduction after initiation of sulfamethoxazole-trimethoprim or metronidazole. J Thromb Thrombolysis 2017;44:88-93. [PMID: 28417267 DOI: 10.1007/s11239-017-1497-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
34 Sedney C, Abu HO, Trymbulak K, Mehawej J, Wang Z, Waring ME, Saczynski J, McManus DD. Sociodemographic, behavioral, and clinical factors associated with low atrial fibrillation knowledge among older adults with atrial fibrillation: The SAGE-AF study. Patient Educ Couns 2021;104:194-200. [PMID: 32690396 DOI: 10.1016/j.pec.2020.07.008] [Reference Citation Analysis]
35 Sestier M, Hillis C, Fraser G, Leong D. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. Curr Oncol Rep 2021;23:113. [PMID: 34342738 DOI: 10.1007/s11912-021-01102-1] [Reference Citation Analysis]
36 Chita DS, Tudor A, Christodorescu R, Buleu FN, Sosdean R, Deme SM, Mercea S, Pop Moldovan A, Pah AM, Docu Axelerad A, Docu Axelerad D, Dragan SR. MTHFR Gene Polymorphisms Prevalence and Cardiovascular Risk Factors Involved in Cardioembolic Stroke Type and Severity. Brain Sci 2020;10:E476. [PMID: 32722170 DOI: 10.3390/brainsci10080476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Kiyosawa N, Watanabe K, Morishima Y, Yamashita T, Yagi N, Arita T, Otsuka T, Suzuki S. Exploratory Analysis of Circulating miRNA Signatures in Atrial Fibrillation Patients Determining Potential Biomarkers to Support Decision-Making in Anticoagulation and Catheter Ablation. Int J Mol Sci 2020;21:E2444. [PMID: 32244749 DOI: 10.3390/ijms21072444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-e267. [PMID: 24682347 DOI: 10.1161/cir.0000000000000041] [Cited by in Crossref: 638] [Cited by in F6Publishing: 423] [Article Influence: 79.8] [Reference Citation Analysis]
39 Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke 2014;9:627-32. [PMID: 24891030 DOI: 10.1111/ijs.12295] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
40 Bernacki GM, Becker RC. Oral anticoagulants in older adults with atrial fibrillation. J Thromb Thrombolysis 2013;36:403-15. [PMID: 23341180 DOI: 10.1007/s11239-013-0869-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Koza E, Diaz J, Chaudhary D, Shahjouei S, Li J, Abedi V, Zand R. Lack of Sex Disparity in Oral Anticoagulation in Atrial Fibrillation Patients Presenting with Ischemic Stroke in a Rural Population. J Clin Med 2021;10:4670. [PMID: 34682796 DOI: 10.3390/jcm10204670] [Reference Citation Analysis]
42 Kundu A, Day KO, Lessard DM, Gore JM, Lubitz SA, Yu H, Akhter MW, Fisher DZ, Hayward RM Jr, Henninger N, Saczynski JS, Walkey AJ, Kapoor A, Yarzebski J, Goldberg RJ, McManus DD. Recent Trends in Oral Anticoagulant Use and Post-Discharge Complications Among Atrial Fibrillation Patients with Acute Myocardial Infarction. J Atr Fibrillation 2018;10:1749. [PMID: 29988239 DOI: 10.4022/jafib.1749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
43 Saczynski JS, Sanghai SR, Kiefe CI, Lessard D, Marino F, Waring ME, Parish D, Helm R, Sogade F, Goldberg R, Gurwitz J, Wang W, Mailhot T, Bamgbade B, Barton B, McManus DD. Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF. J Am Geriatr Soc 2020;68:147-54. [PMID: 31574165 DOI: 10.1111/jgs.16178] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
44 Gándara E, Hammond D, Nagpal S. Role of Vitamin K Antagonists in the Prevention of Thrombotic Bypass Occlusion After Infrainguinal Venous Bypass. Eur J Vasc Endovasc Surg 2016;52:124-31. [PMID: 27142190 DOI: 10.1016/j.ejvs.2016.03.026] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Mihalj M, Carrel T, Urman RD, Stueber F, Luedi MM. Recommendations for Preoperative Assessment and Shared Decision-Making in Cardiac Surgery. Curr Anesthesiol Rep 2020;10:185-95. [PMID: 32431570 DOI: 10.1007/s40140-020-00377-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
46 Wee XT, Ho LM, Ho HK, Lee JY, Yap CW, William H, Chan LCE, Tay HC, Goh CEM, Tan DS. Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore. Clin Cardiol 2017;40:1218-26. [PMID: 29251769 DOI: 10.1002/clc.22811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
47 January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104. [PMID: 24682348 DOI: 10.1161/cir.0000000000000040] [Cited by in Crossref: 1248] [Cited by in F6Publishing: 560] [Article Influence: 156.0] [Reference Citation Analysis]
48 Oertel LB, Fogerty AE. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. Journal of the American Association of Nurse Practitioners 2017;29:551-61. [DOI: 10.1002/2327-6924.12494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 Botto GL, Ameri P, De Caterina R. Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. J Clin Med 2021;10:2866. [PMID: 34203416 DOI: 10.3390/jcm10132866] [Reference Citation Analysis]
50 Hersi AS, Alhebaishi YS, Hamoui O, Hassan T, Khalifa Hamad A, Magdy M, Sabbour H, Shaheen S. Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa. J Saudi Heart Assoc 2018;30:122-39. [PMID: 29910583 DOI: 10.1016/j.jsha.2017.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Abu HO, Saczynski JS, Ware J, Mehawej J, Paul T, Awad H, Bamgbade BA, Pierre-Louis IC, Tisminetzky M, Kiefe CI, Goldberg RJ, McManus DD. Impact of comorbid conditions on disease-specific quality of life in older men and women with atrial fibrillation. Qual Life Res 2020;29:3285-96. [PMID: 32656722 DOI: 10.1007/s11136-020-02578-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Santos IS, Lotufo PA, Brant L, Pinto Filho MM, Pereira ADC, Barreto SM, Ribeiro AL, Thomas GN, Lip GYH, Bensenor IM. Atrial Fibrillation Diagnosis using ECG Records and Self-Report in the Community: Cross-Sectional Analysis from ELSA-Brasil. Arq Bras Cardiol 2021;117:426-34. [PMID: 34550227 DOI: 10.36660/abc.20190873] [Reference Citation Analysis]
53 Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48). Circ: Arrhythmia and Electrophysiology 2017;10. [DOI: 10.1161/circep.116.004267] [Cited by in Crossref: 67] [Cited by in F6Publishing: 27] [Article Influence: 13.4] [Reference Citation Analysis]
54 Gotzmann M, Choudhury DS, Hogeweg M, Heringhaus F, Mügge A, Pflaumbaum A. Risk stratification in patients undergoing interventional left atrial appendage occlusion-Prognostic impact of EuroSCORE II. Clin Cardiol 2020;43:508-15. [PMID: 31967662 DOI: 10.1002/clc.23338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Al-Turaiki AM, Al-Ammari MA, Al-Harbi SA, Khalidi NS, Alkatheri AM, Aldebasi TM, AbuRuz SM, Albekairy AM. Assessment and comparison of CHADS2, CHA2DS2-VASc, and HAS-BLED scores in patients with atrial fibrillation in Saudi Arabia. Ann Thorac Med 2016;11:146-50. [PMID: 27168864 DOI: 10.4103/1817-1737.180026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Raji MA, Lowery M, Lin YL, Kuo YF, Baillargeon J, Goodwin JS. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother 2013;47:35-42. [PMID: 23324508 DOI: 10.1345/aph.1R515] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
57 Senoo K, Lane D, Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circ J. 2014;44:281-290. [PMID: 25278980 DOI: 10.4070/kcj.2014.44.5.281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
58 Austin PC, Lee DS, D'Agostino RB, Fine JP. Developing points-based risk-scoring systems in the presence of competing risks. Stat Med 2016;35:4056-72. [PMID: 27197622 DOI: 10.1002/sim.6994] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 8.7] [Reference Citation Analysis]
59 Bakhai A, Petri H, Vahidnia F, Wolf C, Ding Y, Foskett N, Sculpher M. Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England. J Eval Clin Pract 2021;27:119-33. [PMID: 32314853 DOI: 10.1111/jep.13400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
60 Fastner C, Behnes M, Sartorius B, Yildiz M, Mashayekhi K, El-Battrawy I, Lehmann R, Baumann S, Becher T, Borggrefe M, Akin I. Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. BMC Cardiovasc Disord 2016;16:25. [PMID: 26822890 DOI: 10.1186/s12872-016-0200-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
61 Ishibashi K, Miyamoto K, Kamakura T, Wada M, Nakajima I, Inoue Y, Okamura H, Noda T, Aiba T, Kamakura S, Shimizu W, Yasuda S, Akasaka T, Kusano K. Risk factors associated with bleeding after multi antithrombotic therapy during implantation of cardiac implantable electronic devices. Heart Vessels 2017;32:333-40. [PMID: 27469320 DOI: 10.1007/s00380-016-0879-x] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
62 Baber U, Mastoris I, Mehran R. Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol 2014;11:693-703. [PMID: 25367652 DOI: 10.1038/nrcardio.2014.170] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
63 Rodríguez-Bernal CL, Sanchez-Saez F, Bejarano-Quisoboni D, Riera-Arnau J, Sanfélix-Gimeno G, Hurtado I. Real-World Management and Clinical Outcomes of Stroke Survivors With Atrial Fibrillation: A Population-Based Cohort in Spain. Front Pharmacol 2021;12:789783. [PMID: 34966283 DOI: 10.3389/fphar.2021.789783] [Reference Citation Analysis]
64 Ruocco G, McCullough PA, Tecson KM, Mancone M, De Ferrari GM, D'Ascenzo F, De Rosa FG, Paggi A, Forleo G, Secco GG, Pistis G, Monticone S, Vicenzi M, Rota I, Blasi F, Pugliese F, Fedele F, Palazzuoli A. Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. Am J Cardiol 2020;137:111-7. [PMID: 32991860 DOI: 10.1016/j.amjcard.2020.09.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
65 Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc 2013;2:e000136. [PMID: 24152980 DOI: 10.1161/JAHA.113.000136] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
66 Kuznetsov S, Barcelona R, Josephson RA, Mohan SK. The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation. Curr Neurol Neurosci Rep 2016;16:47. [PMID: 27023335 DOI: 10.1007/s11910-016-0645-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Pennlert J, Asplund K, Carlberg B, Wiklund P, Wisten A, Åsberg S, Eriksson M. Antithrombotic Treatment Following Intracerebral Hemorrhage in Patients With and Without Atrial Fibrillation. Stroke 2015;46:2094-9. [DOI: 10.1161/strokeaha.115.009087] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
68 Stirbys P. Search For The Ideal Antithrombotic Drug: Utopian Task Likely Is Implemented Already. J Atr Fibrillation 2016;9:1432. [PMID: 27909535 DOI: 10.4022/jafib.1432] [Reference Citation Analysis]
69 Wagner LA, Tata AL, Fink JC. Patient safety issues in CKD: core curriculum 2015. Am J Kidney Dis 2015;66:159-69. [PMID: 25987263 DOI: 10.1053/j.ajkd.2015.02.343] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
70 Nansseu JR, Noubiap JJ. Aspirin for primary prevention of cardiovascular disease. Thromb J 2015;13:38. [PMID: 26640414 DOI: 10.1186/s12959-015-0068-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
71 Wan H, Wu S, Wang J, Yang Y, Zhu J, Shao X, Huang B, Zhang H. Body mass index and the risk of all-cause mortality among patients with nonvalvular atrial fibrillation: a multicenter prospective observational study in China. Eur J Clin Nutr 2017;71:494-9. [PMID: 27782115 DOI: 10.1038/ejcn.2016.183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
72 Bajwa RJ, Kovell L, Resar JR, Arbab-Zadeh A, Mandal K, Calkins H, Berger RD. Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Clin Cardiol 2017;40:825-31. [PMID: 28750152 DOI: 10.1002/clc.22764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
73 Tideman PA, Tirimacco R, St John A, Roberts GW. How to manage warfarin therapy. Aust Prescr 2015;38:44-8. [PMID: 26648615 DOI: 10.18773/austprescr.2015.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
74 Heidenreich PA, Solis P, Mark Estes NA, Fonarow GC, Jurgens CY, Marine JE, Mcmanus DD, Mcnamara RL. 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circ: Cardiovascular Quality and Outcomes 2016;9:443-88. [DOI: 10.1161/hcq.0000000000000018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
75 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
76 Jia X, Levine GN, Birnbaum Y. The CHA2DS2-VASc score: Not as simple as it seems. Int J Cardiol 2018;257:92-6. [PMID: 29506745 DOI: 10.1016/j.ijcard.2017.12.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
77 Mallikarjuna Rao Edupuganti M, Marmagkiolis K, Cilingiroglu M, Uretsky BF, Hakeem A. Optimizing selection of antithrombotic therapy in patients requiring PCI and long term anticoagulation. Cardiovasc Revasc Med 2014;15:414-20. [PMID: 25204491 DOI: 10.1016/j.carrev.2014.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Botto GL, Tortora G, Casale MC, Canevese FL, Brasca FAM. Impact of the Pattern of Atrial Fibrillation on Stroke Risk and Mortality. Arrhythm Electrophysiol Rev 2021;10:68-76. [PMID: 34401178 DOI: 10.15420/aer.2021.01] [Reference Citation Analysis]
79 Ramos R, Comas-Cufí M, Alves-Cabratosa L, García-Gil M. Reply: Peripheral Artery Disease and Atrial Fibrillation: The Dangerous Combination. J Am Coll Cardiol 2016;68:238. [PMID: 27386783 DOI: 10.1016/j.jacc.2016.04.029] [Reference Citation Analysis]
80 Abu HO, Saczynski J, Mehawej J, Paul T, Awad H, Bamgbade BA, Pierre-Louis IC, Tisminetzky M, Kiefe CI, Goldberg RJ, McManus DD. Multimorbidity, physical frailty, and self-rated health in older patients with atrial fibrillation. BMC Geriatr 2020;20:343. [PMID: 32917137 DOI: 10.1186/s12877-020-01755-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Seong HJ, Lee K, Kim BH, Son YJ. Cognitive Impairment Is Independently Associated with Non-Adherence to Antithrombotic Therapy in Older Patients with Atrial Fibrillation. Int J Environ Res Public Health 2019;16:E2698. [PMID: 31362337 DOI: 10.3390/ijerph16152698] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
82 Abu HO, Saczynski JS, Mehawej J, Tisminetzky M, Kiefe CI, Goldberg RJ, McManus DD. Clinically Meaningful Change in Quality of Life and Associated Factors Among Older Patients With Atrial Fibrillation. J Am Heart Assoc 2020;9:e016651. [PMID: 32875941 DOI: 10.1161/JAHA.120.016651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
83 Sanghai S, Wong C, Wang Z, Clive P, Tran W, Waring M, Goldberg R, Hayward R, Saczynski JS, McManus DD. Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study. J Am Heart Assoc 2020;9:e014108. [PMID: 32146898 DOI: 10.1161/JAHA.119.014108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
84 Smithard DG. Stroke in Frail Older People. Geriatrics (Basel) 2017;2:E24. [PMID: 31011034 DOI: 10.3390/geriatrics2030024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
85 Kim DH, Lee DI, Ahn J, Lee KN, Roh SY, Shim J, Choi JI, Kim YH. Ischemic stroke risk during long-term follow up in patients with successful catheter ablation for atrial fibrillation in Korea. PLoS One 2018;13:e0201061. [PMID: 30024976 DOI: 10.1371/journal.pone.0201061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Rydberg DM, Linder M, Malmström RE, Andersen M. Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. Eur J Clin Pharmacol 2020;76:867-76. [PMID: 32222786 DOI: 10.1007/s00228-020-02856-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
87 Kim J, Thrift AG, Nelson MR, Bladin CF, Cadilhac DA. Personalized medicine and stroke prevention: where are we? Vasc Health Risk Manag 2015;11:601-11. [PMID: 26664130 DOI: 10.2147/VHRM.S77571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
88 Schwab K, Nguyen D, Ungab G, Feld G, Maisel AS, Than M, Joyce L, Peacock WF. Artificial intelligence MacHIne learning for the detection and treatment of atrial fibrillation guidelines in the emergency department setting (AIM HIGHER): Assessing a machine learning clinical decision support tool to detect and treat non-valvular atrial fibrillation in the emergency department. J Am Coll Emerg Physicians Open 2021;2:e12534. [PMID: 34401870 DOI: 10.1002/emp2.12534] [Reference Citation Analysis]
89 Lopez-Castaneda S, Valencia-Hernández I, Arean C, Godínez-Hernández D, Viveros-Sandoval ME. Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation. Clin Appl Thromb Hemost 2018;24:647-54. [PMID: 28618874 DOI: 10.1177/1076029617711803] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 Thomas MR, Lip GY. Novel Risk Markers and Risk Assessments for Cardiovascular Disease. Circ Res 2017;120:133-49. [PMID: 28057790 DOI: 10.1161/CIRCRESAHA.116.309955] [Cited by in Crossref: 71] [Cited by in F6Publishing: 36] [Article Influence: 14.2] [Reference Citation Analysis]
91 Salvi F, Marchetti A, D'Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a cause of hospitalization in older adults. Drug Saf 2012;35 Suppl 1:29-45. [PMID: 23446784 DOI: 10.1007/BF03319101] [Cited by in Crossref: 84] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
92 Lenihan CR, Montez-Rath ME, Shen JI, Scandling JD, Turakhia MP, Chang TI, Winkelmayer WC. Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation. Nephrol Dial Transplant 2015;30:321-9. [PMID: 25335507 DOI: 10.1093/ndt/gfu323] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
93 Steinberg BA, Schulte PJ, Hofmann P, Ersbøll M, Alexander JH, Broderick-Forsgren K, Anstrom KJ, Granger CB, Piccini JP, Velazquez EJ, Shah BR. Outcomes after nonemergent electrical cardioversion for atrial arrhythmias. Am J Cardiol 2015;115:1407-14. [PMID: 25784514 DOI: 10.1016/j.amjcard.2015.02.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
94 Janardan J, Gibbs H. Combining anticoagulation and antiplatelet drugs in coronary artery disease. Aust Prescr 2018;41:111-5. [PMID: 30116078 DOI: 10.18773/austprescr.2018.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
95 Fava JP, Starr KM, Ratz D, Clemente JL. Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis. Ther Adv Drug Saf 2018;9:405-14. [PMID: 30364869 DOI: 10.1177/2042098618774498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
96 Ye S, Cheng B, Lip GY, Buchsbaum R, Sacco RL, Levin B, Di Tullio MR, Qian M, Mann DL, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Graham S, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Thompson JL, Homma S; WARCEF Investigators. Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. Am J Cardiol 2015;116:904-12. [PMID: 26189039 DOI: 10.1016/j.amjcard.2015.06.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
97 Ouyang P, Wenger NK, Taylor D, Rich-Edwards JW, Steiner M, Shaw LJ, Berga SL, Miller VM, Merz NB. Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. Biol Sex Differ 2016;7:19. [PMID: 27034774 DOI: 10.1186/s13293-016-0073-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
98 Wehbe RM, Yadlapati A. Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. Tex Heart Inst J 2016;43:287-90. [PMID: 27547134 DOI: 10.14503/THIJ-16-5785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
99 Fox KAA, Velentgas P, Camm AJ, Bassand JP, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Dabrowski E, Luo K, Gibbs L, Kakkar AK; GARFIELD-AF Investigators. Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. JAMA Netw Open 2020;3:e200107. [PMID: 32101311 DOI: 10.1001/jamanetworkopen.2020.0107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
100 Li F, Du X, He L, Jiang C, Xia S, Ma C, Dong J. Relationship between serum lipid levels and ischemic stroke in patients with atrial fibrillation: a nested case-control study based on the China Atrial Fibrillation Registry. BMC Cardiovasc Disord 2021;21:424. [PMID: 34496759 DOI: 10.1186/s12872-021-02237-6] [Reference Citation Analysis]
101 Gallagher AM, van Staa TP, Murray-Thomas T, Schoof N, Clemens A, Ackermann D, Bartels DB. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open 2014;4:e003839. [PMID: 24468720 DOI: 10.1136/bmjopen-2013-003839] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
102 Mazurek M, Lip GY. CHA2DS2-VASc score risk factors as predictors of stroke after acute coronary syndrome: Can we really be sure there is no atrial fibrillation? Eur Heart J Acute Cardiovasc Care 2018;7:275-7. [PMID: 28058849 DOI: 10.1177/2048872616688455] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]